IBR Inc. collaborates with service providers, technology suppliers, biotech companies and academia to complement its broad portfolio of bioanalytical services, bringing-in innovation and offering cutting-edge technologies to support pharmaceutical development and help clients to success in market.
Dualsystems is IBR Inc’s partner for the deconvolution of cell surface interactions (and proteomes) on living cells through a combination of chemoproteomics and mass spectrometry. With Dualsystems proprietary technology platforms “LRC-TriCEPS” and “LRC-HATRIC” the targets (and off targets) of ligands are identified in their natural microenvironment (intact plasma membrane even of primary cells) without the need of any genetic modification. Further, the platforms can be used to identify new drug targets by elucidating ligand-receptor interactions important in cell-cell communication.
Gyrolab is the world leader in microfluidic technologies and immunoassay miniaturization and automation. Gyrolab nanoliter-scale technology offers broad dynamic range and helps developing immunoassays faster, with high data quality, reliably and precision. Together with Gyrolab we in-house develop immunoassays for detection of biomarkers, ADAs and drug-target binding assays. IBR Inc.’s scientist keep their knowledge on Gyrolab features and applications constantly up-to-date. Read Gyrolab’s interview with IBR Inc.
Meso Scale Discovery (MSD), a partner of IBR Inc., has developed an advanced immunoassay platform combining electrochemiluminescence and MULTI‑ARRAY technology. The MSD platform provides high sensitivity and multiplex functionality for quantification of multiple analytes, even in complex matrices. We work closely together with Meso Scale Discovery to in-house develop new pharmacological applications, such as ligand binding assays and assays for detection of cytokines and other biomarkers, and ADAs. The team of IBR Inc. is always up-to-date on the latest news on MSD technology features and applications.